Poor
Mostly Unaligned
Patient Risk:
Moderate
Summary
Multiple claims about taking acyclovir less frequently (efficacy, resistance, recovery time, morbidity/mortality, recurrence) are not supported by the provided label excerpts. Some adherence and missed-dose instructions are broadly consistent with standard missed-dose guidance, but the supplied label excerpts do not provide dosing-frequency warnings or missed-dose instructions to verify them. Indication and mechanism statements are partially supported.
Category Scores
Accurate Statements
Acyclovir is prescribed to treat viral infections including herpes simplex virus (HSV), varicella-zoster virus (VZV), and cytomegalovirus (CMV).
Unsupported as written vs provided excerpts: the label excerpts explicitly support herpes zoster (shingles), genital herpes (initial and recurrent), and chickenpox (varicella). HSV/VZV are not explicitly listed as such in the provided excerpts, and CMV is not included.
Acyclovir works by inhibiting viral replication.
Not explicitly supported by the provided excerpts; no mechanism statement was included in the supplied label text.
If a dose of acyclovir is missed, it should be taken as soon as possible.
Not supported by the provided excerpts; missed-dose instructions are not present in the supplied label text.
If a missed acyclovir dose is almost time for the next dose, the missed dose should be skipped and the regular dosing schedule continued.
Not supported by the provided excerpts; missed-dose instructions are not present in the supplied label text.
If a dose of acyclovir is missed, a double dose should not be taken to make up for the missed one.
Not supported by the provided excerpts; missed-dose instructions are not present in the supplied label text.
Unsupported Statements
Taking acyclovir less frequently than recommended can reduce the effectiveness of the medication.
The provided label excerpts include specific dosing regimens and timing (e.g., 5 times daily; initiate early), but they do not state that taking less frequently reduces effectiveness.
Taking acyclovir less frequently can allow the virus to replicate more freely.
No label language in the provided excerpts states that taking less frequently allows viral replication more freely.
Taking acyclovir less frequently can increase the risk of viral resistance to the medication.
No provided label excerpt discusses resistance risk related to under-dosing or reduced dosing frequency.
Taking acyclovir less frequently can lead to the development of resistance that makes the medication less effective in the long run.
No provided label excerpt discusses resistance or long-term reduced effectiveness due to reduced dosing frequency.
Taking acyclovir less frequently can prolong recovery time.
Although trials are described with specific dosing frequency and timing, the provided excerpts do not state that reduced dosing frequency prolongs recovery time.
Taking acyclovir less frequently can increase morbidity and mortality.
No provided label excerpt connects reduced dosing frequency to morbidity/mortality.
Taking acyclovir less frequently can increase the risk of recurrence of the viral infection.
The provided label excerpt includes suppressive therapy duration/re-evaluation, but does not state that reduced dosing frequency increases recurrence risk.
Acyclovir is prescribed to treat viral infections including herpes simplex virus (HSV), varicella-zoster virus (VZV), and cytomegalovirus (CMV).
The provided label excerpts list herpes zoster, genital herpes, and chickenpox; they do not mention HSV, VZV, or CMV (and CMV is not included).
Acyclovir works by inhibiting viral replication.
No provided label excerpt states a mechanism of action.
Acyclovir is generally taken twice or three times a day for a period of 5-10 days.
The provided label dosing regimens in Section 2 are generally 5 times daily for 7-10 days (e.g., herpes zoster 800 mg every 4 hours, 5 times daily for 7-10 days) and other regimens (e.g., 2 times daily suppressive therapy). The 'twice or three times a day' generalization is not supported by the excerpts.
It is essential to adhere to the prescribed acyclovir dosage even if the infection is mild.
The provided label excerpts do not state 'essential' adherence in the context of mild infection.
Taking acyclovir less frequently even for a mild infection can lead to reduced efficacy.
No provided label excerpt links reduced dosing frequency to reduced efficacy.
Taking acyclovir less frequently even for a mild infection can increase the risk of resistance.
No provided label excerpt links reduced dosing frequency to resistance risk.
If a dose of acyclovir is missed, it should be taken as soon as possible.
Missed-dose instructions are not included in the provided label excerpts.
If a missed acyclovir dose is almost time for the next dose, the missed dose should be skipped and the regular dosing schedule continued.
Missed-dose instructions are not included in the provided label excerpts.
If a dose of acyclovir is missed, a double dose should not be taken to make up for the missed one.
Missed-dose instructions are not included in the provided label excerpts.
Contradictions
Important Omissions
Specific FDA-labeled dosing frequency/timing and regimen-dependent dosing (e.g., herpes zoster 800 mg 5 times daily for 7-10 days; genital herpes initial vs suppressive vs intermittent; chickenpox dosing by age/weight; renal impairment dose modification).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Claims about under-dosing consequences (resistance, morbidity/mortality, delayed recovery) are not supported by the provided label excerpts, and missed-dose guidance is also not supported by the excerpts. The incorrect indication/mechanism and incorrect dosing-frequency generalization could mislead dosing and disease targeting if followed without confirmation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Multiple statements (especially effects of taking less frequently, resistance/morbidity/mortality, dosing-frequency generalization, and included indications including CMV) are not supported by the provided prescribing-information excerpts.
Suggested Improvement
Restrict claims to what is explicitly present in the provided label excerpts (approved indications: herpes zoster, genital herpes, chickenpox; and specific labeled dosing regimens and early initiation language). Remove unsupported or label-inconsistent generalizations about under-dosing outcomes, resistance, and missed-dose instructions unless corresponding label text is provided.